# Stephen A. Harrison

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/stephen-a-harrison/

## Facts

| Field | Value |
| --- | --- |
| Citations | 68,555 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 117 |
| i10-index | 351 |
| OpenAlex ID | https://openalex.org/A5091625375 |
| ORCID iD | https://orcid.org/0000-0001-8285-2204 |
| Works | 748 |

## Researcher papers

- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-3/)
- [A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis](https://scholariq.org/papers/a-placebo-controlled-trial-of-subcutaneous-semaglutide-in-nonalcoholic/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening](https://scholariq.org/papers/elafibranor-an-agonist-of-the-peroxisome-proliferator-activated-receptor-and/)
- [A multisociety Delphi consensus statement on new fatty liver disease nomenclature](https://scholariq.org/papers/a-multisociety-delphi-consensus-statement-on-new-fatty-liver-disease-2/)
- [A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH](https://scholariq.org/papers/a-randomized-controlled-trial-of-the-pan-ppar-agonist-lanifibranor-in-nash/)
- [Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis](https://scholariq.org/papers/diagnostic-accuracy-of-non-invasive-tests-for-advanced-fibrosis-in-patients-with/)
- [Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials](https://scholariq.org/papers/selonsertib-for-patients-with-bridging-fibrosis-or-compensated-cirrhosis-due-to/)
- [Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis](https://scholariq.org/papers/diagnostic-accuracy-of-elastography-and-magnetic-resonance-imaging-in-patients/)
- [Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis](https://scholariq.org/papers/performance-of-non-invasive-tests-and-histology-for-the-prediction-of-clinical/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Diet, Metabolism, and Disease](https://scholariq.org/topics/diet-metabolism-and-disease/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.